Comparative Effectiveness and Safety of Ustekinumab versus Anti–TNF Therapy in Crohn Disease: A Systematic Review
This systematic review indicates that while ustekinumab and anti-TNF therapies demonstrate comparable overall effectiveness and safety in Crohn disease, anti-TNF agents may offer superior early clinical response whereas ustekinumab provides greater treatment durability in biologic-experienced patients, supporting individualized therapy selection.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Crohn disease is a chronic condition where the body's immune system mistakenly attacks the digestive tract, causing inflammation that can damage any part of the gut from the mouth to the anus. This inflammation is not just a surface irritation; it can burrow deep through the layers of the intestinal wall, leading to painful symptoms, blockages, and sometimes the need for surgery. For decades, the most powerful tools doctors had to calm this fire were a class of drugs called anti-tumor necrosis factor agents, or anti-TNFs for short. These medicines work by blocking a specific protein that drives the inflammation. While they helped many patients, a significant number of people either did not respond to them at all or eventually stopped responding as their bodies built up a tolerance. This left doctors with a difficult question: when the first line of defense fails, what is the best next step?
In recent years, a newer type of medicine called ustekinumab has emerged as a strong alternative. Unlike anti-TNFs, which target a single inflammatory protein, ustekinumab blocks two different proteins that work together to fuel the immune response. Because it works differently, it seemed like a promising option for patients who had already tried and failed the older drugs. However, for a long time, there was no clear consensus on whether this newer drug was actually better than the older ones, or if they were simply different tools for different jobs. To answer this, a team of researchers from universities and hospitals across Mexico and beyond decided to look at the entire body of existing evidence. They gathered data from ten different studies, ranging from large randomized trials to real-world observations, to compare how well these two types of medicines worked and how safe they were for adults with Crohn disease.
The researchers found that, for the most part, these two treatments are remarkably similar in their ability to bring about remission and keep patients safe. When looking at the big picture, neither drug proved to be a clear winner over the other in terms of overall effectiveness or safety. Both treatments successfully reduced inflammation, healed the lining of the intestine, and prevented serious complications like hospitalization or surgery at comparable rates. The safety profiles were also nearly identical, with both groups experiencing similar rates of side effects and infections. This suggests that for a patient starting treatment for the first time, either option is a valid choice, and the decision can be guided by other factors such as cost, availability, or patient preference.
However, the story becomes more nuanced when looking at the timing of the treatment and the patient's history. In the early stages of treatment, particularly during the first few months, some studies suggested that the older anti-TNF drugs might work slightly faster to produce a clinical response. Patients on these drugs sometimes reported feeling better sooner than those on ustekinumab. Yet, this early advantage did not always translate into long-term superiority. Over the course of a year, the rates of deep healing and sustained remission between the two groups largely evened out. The most significant difference appeared when looking at patients who had already tried other biologic medicines before. In this group, people who switched to ustekinumab tended to stay on their medication longer and were less likely to stop treatment compared to those who switched to another anti-TNF drug. This suggests that for patients who have already failed a previous therapy, the newer drug might offer a more durable solution, keeping them in remission for a longer period.
The researchers emphasized that these findings do not point to a single "best" drug for everyone. Instead, the results support a personalized approach to care. For a patient who has never taken biologic medication before, an anti-TNF drug might be a logical first choice, especially if a rapid response is needed. But for a patient who has already tried and failed an anti-TNF, switching to ustekinumab appears to be a smart strategy to maintain long-term health. The study also highlighted that the definition of "success" can vary from one doctor to another, with some focusing on how a patient feels and others on what an endoscopy camera sees inside the gut. Despite these variations in how the data was collected, the overall message remained consistent: both medicines are powerful tools that can effectively manage this difficult disease. The choice between them is no longer about finding a magic bullet that works for everyone, but rather about matching the right tool to the specific needs and history of the individual patient.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.